Navigation Links
First identification of a strong oral carcinogen in smokeless tobacco
Date:8/22/2012

PHILADELPHIA, Aug. 22, 2012 Scientists today reported identification of the first substance in smokeless tobacco that is a strong oral carcinogen ― a health risk for the 9 million users of chewing tobacco, snuff and related products in the U.S. ― and called upon the federal government to regulate or ban the substance.

The researchers reported here at the 244th National Meeting & Exposition of the American Chemical Society, the world's largest scientific society. The meeting, which continues through Thursday, features more than 8,600 reports on new developments in science, with an anticipated attendance of 14,000 scientists and others.

"This is the first example of a strong oral cavity carcinogen that's in smokeless tobacco," said Stephen Hecht, Ph.D., who led the study. "Our results are very important in regard to the growing use of smokeless tobacco in the world, especially among younger people who think it is a safer form of tobacco than cigarettes. We now have the identity of the only known strong oral carcinogen in these products."

Evidence has been accumulating for years that people who use smokeless tobacco have an increased risk of cancer of the mouth, esophagus and pancreas. Scientists also knew that smokeless tobacco users are exposed to a variety of carcinogens and experience some damage to their genetic material impairing its normal function. But until now, no substance in these products was clearly implicated as a cause of mouth cancer, explained Hecht, who is at the University of Minnesota.

Hecht's team identified the culprit as (S)-NNN, one of a family of hundreds of compounds called nitrosamines, most of which are carcinogenic, capable of causing cancer. Nitrosamines occur in a variety of foods, ranging from beer to bacon, and also form naturally in the stomach when people eat foods containing high levels of nitrite. But nitrosamine levels in smokeless tobacco are far higher than in food.

To do it, they gave laboratory rats a low dose of two forms of NNN, suspected carcinogens in smokeless tobacco, for 17 months in doses roughly equivalent to a person consuming half of a tin of smokeless tobacco every day for 30 years. One substance, (S)-NNN, induced large numbers of oral and esophageal tumors in the rats.

"The most popular brands of smokeless tobacco that are sold in the U.S. have unacceptably high levels of this particular carcinogen," explained Hecht. "And smokeless tobacco is a known cause of oral cancer. Obviously, we need to decrease the levels of this material in all smokeless tobacco products or eliminate it altogether." Hecht adds that removing (S)-NNN from these products is feasible. In fact, some products on store shelves today have reduced levels of the carcinogen.

Hecht explained that the U.S. Food and Drug Administration has the authority to regulate tobacco products, but no regulations on the levels of specific carcinogens exist yet. "My suggestion is that levels of (S)-NNN in smokeless tobacco be decreased to below 10 parts per billion. That would make it more consistent with the levels of nitrosamines in food products," he said. (S)-NNN also is in cigarettes and other smoked tobacco items, and he suggested that the substance be regulated in these products, as well.


'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
215-418-2056 (Philadelphia Press Center, Aug. 17-23)
202-872-6042

Michael Woods
m_woods@acs.org
215-418-2056 (Philadelphia Press Center, Aug. 17-23)
202-872-6293
American Chemical Society


Source:Eurekalert

Related medicine news :

1. IHME professor named first health measurement winner of prestigious innovation award
2. FDA Gives Nod to First Drug for Diabetic Eye Disease
3. Mayo Clinic completes first genome-wide analysis of peripheral T-cell lymphomas
4. Women and Children First? Not So, Says Study
5. WPI to host international workshop focused on technology solutions for first responders
6. First Huntingtons disease center established in Washington, D.C., area
7. Study Gives First Evidence That Adult Human Lungs Can Regrow
8. Hookah smoking increasingly common among first-year college women
9. Sohn Conference and Damon Runyon Cancer Research Foundations name first pediatric research fellows
10. Scientists first to see trafficking of immune cells in beating heart
11. First-of-its-kind approach nanomedicine design effectively targets cancer with decreased toxicity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... Spain (PRWEB) , ... April 24, 2017 , ... ... on the development of next generation neuro-thrombectomy systems for the treatment of Acute ... and manufacture its ANCD BRAIN device as the product advances towards regulatory and ...
(Date:4/23/2017)... ... 2017 , ... "An event Horizon is a place where the laws of ... and Music. These are created as Metaphysical Transformations where music, which is the origin ... the ultimate singularity.", -- Karen Salicath Jamali , Karen will also preview her upcoming ...
(Date:4/22/2017)... ... ... Ecommerce sales have grown every year since the 1990’s, with 2016 retail ... of rapid innovation and growth are often neglected in the name of progress. As ... individual’s job to give something back to the planet that provides the resources needed ...
(Date:4/22/2017)... White Plains, NY (PRWEB) , ... April 22, ... ... Quarterly Report, which shows that U.S. consumers can save an average of 70% ... Even greater savings (up to 97%) are available when purchasing from other countries. ...
(Date:4/22/2017)... Capistrano (PRWEB) , ... April 22, 2017 , ... The San Juan Capistrano summer ... released a parenting report outlining the need for summer camps to provide physical activities for ... Importance of Physical Activity In Summer Camps , With an increase in specialty camps that ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... new treatments for cancer and other unmet medical ... announced underwritten public offering of 23,625,084 shares of ... of $2.00 per share, before deducting underwriting discounts ... Sorrento.  The net proceeds to Sorrento from this ...
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
(Date:4/18/2017)... April 18, 2017 Cogentix Medical, Inc. (NASDAQ: ... the Urology, Uro/Gyn and Gynecology markets with innovative and ... quarter ended March 31, 2017 after the market close ... Company will host a conference call and webcast to ... May 2, 2017 at 4:30 p.m. Eastern Time (3:30 ...
Breaking Medicine Technology: